BL.13
NCT03768570
BL13
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
Status:
Recruiting
II
Phase
2nd+
Line of Therapy
Advanced / Metastatic
Disease Stage
Biomarker(s)
PD-1, PD-L1
Investigational
Product
Durvalumab
IgG1κ monoclonal antibody (i.v.)
Treatment Arms
o No Intervention: Surveillance
o Active Comparator: Durvalumab